Spirig HealthCare

What Spirig HealthCare does

Spirig HealthCare AG is a Switzerland-based pharmaceutical company headquartered in Egerkingen (Solothurn) and operating as a wholly-owned subsidiary of STADA Arzneimittel AG since 2012. The company supplies a portfolio spanning approximately 150 generic medicines across more than 560 dosage strengths, biosimilars, specialty care products (including advanced Parkinson's disease treatments), and a growing branded Consumer Healthcare franchise. Its OTC brand portfolio includes Mebucaïne N, Pulmex, NasoboL INHALO, Antistax forte, Nizoral, Terzolin, and Cerumenol — several of which are leading or generational brands in their respective Swiss categories. The current legal entity was established in 2011, building on a Swiss pharmaceutical heritage dating to 1948.

The company operates its own pharmaceutical manufacturing, packaging, and GDP-certified distribution infrastructure, including a fully automated high-bay warehouse in Egerkingen (built 2006-2009) and a new proprietary logistics center in Wangen an der Aare opened in October 2025 (2,600 m², 2,000+ picking stations, Pick-by-Light commissioning, AMI SMART-FLEXDEPOT automated storage, WiFi temperature monitoring, and an own delivery fleet for emergency life-saving medicine deliveries within hours). The e-Spirig online platform provides electronic ordering, invoice management, inventory tracking, and physician-software integration for registered healthcare professionals.

Spirig generates revenue primarily through one-time product sales to Swiss physicians with Selbstdispensation (self-dispensing) rights, pharmacies, drugstores, hospitals, and care homes. Pricing for generics is set 20-70% below originator products, and consumer brands are distributed exclusively through regulated pharmacy and drugstore channels. Go-to-market is anchored by a multi-region field sales force (Ärzte Schweiz Ost/Mitte, Westschweiz/Ticino), Key Account Managers for Specialty Care, Women's Health, and physician networks, supplemented by the e-Spirig self-serve portal. As the #3 player in the Swiss generics market and part of the international STADA group, Spirig combines local Swiss distribution depth with group-level scale and pipeline access.

Name

Spirig HealthCare

Legal name

Spirig HealthCare AG

Website

https://spirig-healthcare.ch

Company type

Private

Founded year

1948

Operating status

Operating

Headcount range

51–100 employees

Short description

Spirig HealthCare AG is a Swiss pharmaceutical company (Egerkingen, subsidiary of STADA Arzneimittel AG since 2012) that supplies generics, biosimilars, specialty care products, and leading OTC brands to physicians, pharmacies, drugstores, hospitals, and care homes across Switzerland via its own GDP-certified distribution network.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Full-Line Pharmaceutical Wholesalers (HLAIAJAA)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), Specialty Care Pharmaceuticals (HLAIAAAB), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Consumer healthcare products
• Specialty care medicines
• Pharmaceutical wholesale distribution
• OTC brand portfolio

Headquarters

HQ city

Egerkingen

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Generic Pharmaceuticals Sales: Spirig HealthCare generates revenue primarily from the sale of generic pharmaceuticals (~150 products) to physicians with self-dispensation rights, pharmacies, and other healthcare providers in Switzerland. Generics contain proven active ingredients at 20-70% lower prices than originals, enabling affordable healthcare access. The company is ranked #3 in the Swiss generics market.
2. Consumer Healthcare Product Sales: Sale of branded OTC products including Mebucaïne N, Pulmex, NasoboL INHALO, and Antistax forte exclusively through pharmacies and drugstores. These are leading brands in their respective categories, sold as off-patent, established products.
3. Specialty Care & Biosimilars: Revenue from specialty pharmaceutical products including advanced treatments for complex conditions (e.g., Morbus Parkinson, oncology) and biosimilar medications offering cost-effective alternatives to originator biologics.
4. Pharmaceutical Wholesale Logistics: As a licensed pharmaceutical wholesaler (GDP-certified), Spirig HealthCare operates its own distribution infrastructure for its products and related logistics services, including order processing, storage, and last-mile delivery across Switzerland, supporting supply security for healthcare providers.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels9 records

Core offering

Spirig HealthCare AG manufactures and distributes a portfolio of more than 250 generic pharmaceutical products across 560+ dosage strengths, complemented by specialty care medicines, biosimilars, and a portfolio of established consumer healthcare OTC brands (Mebucaïne N, Pulmex, NasoboL INHALO, Antistax forte, Nizoral, Terzolin, Cerumenol). The company is ranked #3 in the Swiss generics market and operates its own GDP-certified pharmaceutical wholesale logistics, distributing exclusively through Swiss physicians with self-dispensation rights, pharmacies, drugstores, hospitals, and care homes.

Product overview

Spirig HealthCare operates as a pharmaceutical company offering a diversified portfolio organized into four core segments: Generics (approximately 150 medications across 200 active substances and 750+ dosages), Biosimilars (biotechnologically manufactured drugs equivalent to reference products), Specialty Care (specialized medications for complex conditions including advanced Parkinson's disease), and Consumer Healthcare OTC brands. The Consumer Healthcare portfolio includes acquired leading brands: Mebucaïne N (throat lozenges), Pulmex (cold/cough ointment), NasoboL INHALO (respiratory inhalation tablets), Antistax forte (venous tablets), Nizoral (dermatology products), Terzolin (scalp treatments), and Cerumenol (ear care). The company also provides integrated services including the E-Spirig online ordering platform with physician software connectivity, quality assurance consulting, certified medical instrument reprocessing (sermaX), medication storage automation (AMI SMART-FLEXDEPOT, KLS-Solo-System), and professional training workshops. Since 2012, Spirig HealthCare has been part of the STADA Arzneimittel AG group.

Differentiator

Problem solved

Functional benefit

Brands

• Mebucaïne: Throat lozenges for sore throat relief with dual action - pain-relieving lidocaine and antiseptic cetylpyridinium
• Pulmex
• NasoboL INHALO
• Antistax

Products and services

• Generika (Generic Pharmaceuticals) Generic pharmaceuticals with proven active ingredients offered at 20-70% lower prices than originals. Portfolio includes approximately 150 medications and around 200 active substances across more than 750 dosages and pack sizes. Sold to Swiss physicians with self-dispensation rights, pharmacies, hospitals, and care homes.
• Biosimilars

Quantifiable outcome

• Generic pricing 20-70% below originator drug prices, contributing to affordable healthcare access in Switzerland
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

One partnership is on record.

• STADA Arzneimittel AGcoreStrategic or Co-development Partner · 1 January 2012Spirig HealthCare AG has been part of STADA Arzneimittel AG, a German international healthcare company, since 2012. This parent-subsidiary relationship provides Spirig with access to STADA's global product pipeline, international network, and shared corporate resources including compliance systems, the STADA Health Report platform, and group-wide standards in quality, compliance, and corporate culture (Integrity, Entrepreneurship, Agility, One STADA). The partnership enables Spirig to expand its product assortment and bring innovative products to market faster in Switzerland.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Galexis AG: Switzerland's largest pharmaceutical wholesaler (part of Galenica Group), GDP-certified, distributing generics, OTC, and specialty pharma to pharmacies, physicians and hospitals nationwide. Direct competitor to Spirig HealthCare's GDP-certified wholesale and distribution operations in the same Swiss market.
• Mepha AG: Leading Swiss generics manufacturer and distributor (part of Teva), offering a broad generics portfolio to pharmacies, physicians and hospitals in Switzerland. Comparable to Spirig HealthCare in generics portfolio depth, channels served, and Swiss regulatory exposure.
• Amedis AG: Swiss pharmaceutical wholesale and pre-wholesale distributor serving pharmacies, drugstores and self-dispensing physicians. Direct competitor in Spirig's physician-SD and pharmacy distribution channels, with overlapping GDP-compliant logistics and Swiss-only footprint.
• Gebro Pharma AG: Swiss specialty pharmaceutical company marketing branded Rx and OTC products (e.g., Flector, Inflamac, Crestor) in Switzerland through physician and pharmacy channels. Comparable to Spirig's specialty-care and consumer-healthcare business in Swiss market scope and channel model.

Regional players

• Dr. A. & L. Schmidgall GmbH & Co KG: Austrian pharma manufacturer/distributor of branded OTC and generics, exporting to neighboring markets including Switzerland. Comparable to Spirig in product portfolio mix (OTC, generics, branded Rx), focused on the German-speaking market, but commercially operated from a different home geography.

Broad incumbents

• Galenica AG: Swiss pharmacy retail, wholesale (through Galexis/Amedis), and pharmaceutical services group. Comparable to Spirig at the broader Swiss pharma-distribution level through its owned wholesalers and exclusive pharmacy-channel relationships.
• Sandoz AG: Swiss-headquartered global generics and biosimilars major (spun off from Novartis in 2023). Comparable to Spirig in generics and biosimilars across the same Swiss customer base, with materially broader portfolio, scale, and pipeline.
• STADA Arzneimittel AG: Spirig HealthCare's German parent company since 2012, operating the same generics/biosimilars/consumer healthcare business model across Europe. Comparable as the broader group-level execution of the strategy Spirig applies at Swiss-country level.
• Teva Pharmaceutical Industries Ltd. Global generics and specialty pharma leader with strong Swiss presence through Mepha. Comparable to Spirig in portfolio composition (generics, biosimilars, specialty) and channel coverage, with vastly larger scale and R&D infrastructure.

Others

• Bayer Consumer Health: Major OTC consumer healthcare brand owner (e.g., Aspirin, Bepanthen, Claritin) with established Swiss pharmacy-channel presence. Comparable to Spirig's consumer healthcare portfolio (Mebucaïne, Pulmex, Antistax) at the OTC brand and channel level.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/spirig-healthcare-ag

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spirig HealthCare